Tag: CX 2022
Experts react to “compelling” 36-month IN.PACT AV Access trial data
NOTE: This video is ONLY available to watch in selected countries and geographies
Robert Shahverdyan (Hamburg, Germany), Matteo Tozzi (Varese, Italy), Alexandros Mallios (Paris,...
Roundtable: Will latest IN.PACT AV Access data impact practice and can...
NOTE: This video is ONLY available to watch in selected countries and geographies
In this Renal Interventions roundtable, Andrew Holden (moderator; Auckland, New Zealand) is...
Sirogen™: A potential solution for improving arteriovenous fistula maturation
This advertorial is sponsored by Vascular Therapies
Arteriovenous fistula (AVF) maturation is a pivotal event in patients requiring haemodialysis. Maximising the number of fistulas that...
New sirolimus data provide encouragement despite “potentially disappointing” efficacy results
The results of a small-scale pilot study from Asia have indicated “potentially disappointing” results with a novel drug-eluting balloon in treating dysfunctional arteriovenous access...
IN.PACT AV DCB “first and only” to show sustained and superior...
Medtronic has announced new randomised controlled data demonstrating the sustained and superior performance of the IN.PACT AV drug-coated balloon (DCB) compared to percutaneous transluminal...
Restorative Axess graft demonstrates promising patency and safety in first-in-human study
The preliminary results from a clinical trial assessing a restorative haemodialysis access graft have shown promising early puncturing, patency and safety data. These findings...
CX returns to in-person format once more in the London spring
Charing Cross (CX) chair Roger Greenhalgh welcomes the vascular community to this year's symposium, due to be held 26–28 April in London, UK, and...
CX 2022: Nicholas Inston on Vascular Access Challenges
Nicholas Inston (Birmingham, UK) talks to CX about the challenges in creation, maintenance and salvage of vascular access in patients with end stage renal disease....